Rallybio shares are trading higher after the company announced that it will receive a $50 million termination fee from former merger partner Candid Therapeutics.

Benzinga Newsdesk www.benzinga.com Positive 77.6%

Neg 0% Neu 0% Pos 77.6%

Comments

No comments yet. Be the first!